News Kyowa Kirin Co., Ltd. OTC Markets

Equities

KYKOY

US50156R1077

Delayed OTC Markets Other stock markets 14:50:18 16/07/2024 BST			5-day change	1st Jan Change
19.85 ^USD	+0.27%		0.00%	+22.18%

07-03	Kyowa Kirin Buys Back Shares	MT
07-02	Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kyowa Kirin Buys Back Shares	07-03	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	07-02	CI
Kyowa Kirin : Announces Application for Additional Formulation of “LUMICEF® Subcutaneous Injection 210 mg Pen” in Japan	06-28	PU
Ex-dividend day for interim dividend	06-26	FA
Kyowa Kirin Repurchases 3.3 Million Shares in May	06-05	MT
Kyowa Kirin : Announces Approval for Partial Change of Approved Indication of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan (243KB)	05-17	PU
Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 First Quarter (0B)	05-09	PU
Kyowa Kirin's Profit Up 15% in Q1	05-07	MT
Kyowa Kirin : Results Presentation Fiscal 2024 First Quarter (0B)	05-07	PU
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	05-06	AQ
Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April	05-06	MT
BridgeBio Pharma Shares Decline After Q1 Financial Results	05-02	MT
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies	04-15	AQ
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome	04-15	BU
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	04-08	RE
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	04-03	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	04-02	CI
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	03-25	MT
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	03-25	MT
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	03-20	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kyowa Kirin Co., Ltd. OTC Markets

Equities

KYKOY

US50156R1077

Summary

Filters